Lilly declares third-quarter 2025 dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Citi Reiterates Buy Rating on Eli Lilly (LLY)
June 25, 2025 5:11 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $1,190.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Given compelling data, Lilly and Novo have reframed obesity as a treatable disease, not just a lifestyle/behavior-based condition. The obesity paradigm should further... More
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
June 23, 2025 12:14 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "One of the side effects of the dramatic weight loss of GLP-1 based medications is that people also lose muscle/lean body mass. LLY, REGN, BHVN and other companies are developing drugs targeting the activin receptor pathway with the goal of preventing/slowing muscle mass loss. LLY's program broadly blocks the receptors (and hence activins, myostatin, and GDF11 ligands simultaneously), while REGN is focused on selectively blocking two ligands (myostatin and activin A)... More
